Valley National Bancorp’s Alexion Pharmaceuticals ALXN Stock Holding History

Valley National Bancorp’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	$3K	Buy	+16	New	+$2.96K	﹤0.01%	214

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Valley National Bancorp's ALXN Position: Q4 2014 in Review

Valley National Bancorp opened a new position in Alexion Pharmaceuticals (ALXN) in Q4 2014: 16 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #214 among its holdings.

579 funds tracked by Wall St. Rank hold ALXN as of Q4 2014.

Valley National Bancorp held 16 shares of Alexion Pharmaceuticals worth $3K as of Q4 2014.
Alexion Pharmaceuticals was a new Valley National Bancorp position in Q4 2014.
Alexion Pharmaceuticals made up ﹤0.01% of Valley National Bancorp's portfolio in Q4 2014, its #214 holding.
579 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2014.

Based on Valley National Bancorp's 13F filing for Q4 2014, filed 9 Feb 2015.